ANI Pharmaceuticals

Yahoo Finance • 10 months ago

13 Stocks That Will Double in 2024

In this article, we discuss the 13 stocks that will double in 2024. To skip the detailed analysis of the recent events in the stock market, go directly to the 5 Stocks That Will Double in 2024. Last year turned out to be wondrous for the... Full story

Yahoo Finance • last year

ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conferenc... Full story

Yahoo Finance • last year

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -... Full story

Yahoo Finance • last year

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences

BAUDETTE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate a... Full story

Yahoo Finance • last year

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, p... Full story

Yahoo Finance • last year

ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Cortrophin Gel is the only FDA-approved purified corticotropin (ACTH) indicated for the treatment of appropriate patients with acute gouty arthritis flares New 1-mL size furthers ANI’s commitment to providing ACTH options for appropriate... Full story

Yahoo Finance • last year

ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023

BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at t... Full story

Yahoo Finance • last year

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP

BAUDETTE, Minn., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application... Full story

Yahoo Finance • last year

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%

BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (... Full story

Yahoo Finance • last year

ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BAUDETTE, Minn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at th... Full story

Yahoo Finance • last year

ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE... Full story

Yahoo Finance • last year

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP): Is Breakeven Near?

With the business potentially at an important milestone, we thought we'd take a closer look at ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) future prospects. ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and... Full story

Yahoo Finance • 2 years ago

ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock

BAUDETTE, Minn., May 12, 2023--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) ("ANI" or the "Company") today announced the pricing of its previously announced underwritten public offering of 1,898,735 shares of its common stock... Full story

Yahoo Finance • 3 years ago

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

Partnership drives commercial excellence through precision engagement to benefit patients in need of options BAUDETTE, Minn. and PLEASANTON, Calif., June 21, 2022 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) and Veeva Systems... Full story

Yahoo Finance • 3 years ago

The past three years for ANI Pharmaceuticals (NASDAQ:ANIP) investors has not been profitable

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shareholders should be happy to see the share price up 11% in the last month. Meanwhile over the last three years the stock has dropped hard. Indeed, the share price is down a tragic 61% in the last... Full story